Disclaimer:

This Report was prepared by Paisley and Habermas, Inc. at the request of American Biogenetic Sciences, Inc. While the Company has reviewed the Report to confirm the correctness of factual statements about the Company and its products contained in the report, the assumptions, conclusions, and analysis of the current and potential markets, the technology and products addressing various markets, the efficacy of various products and treatments, and the projections and other forward-looking statements contained in the report are those of Paisley and Habermas, Inc.

Statements in this Report that are not strictly historical are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. That act provides a "safe harbor" for forward-looking statements to encourage companies to provide prospective information so long as those statements are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those discussed in the Report. Such forward-looking statements are subject to a number of known and unknown risks and uncertainties that, in addition to general economic and business conditions (both in the United States and in the overseas markets where the Company intends to distribute products), could cause the Company’s anticipated results, performance and achievements to differ materially from those described or implied in the forward-looking statements.

Examples of these risks and uncertainties include, without limitation, the Company’s ability to complete products under development and to maintain superior technological capability, foresee changes and identify, develop and commercialize innovative and competitive products, obtain widespread acceptance of its products by the medical community, including the reliability, safely and effectiveness of such products, meet competition, comply with various governmental regulations related to the Company’s products, successfully expand its manufacturing capability, attract and retain technologically qualified personnel, and generate cash flows and obtain collaborative and other arrangements with pharmaceutical companies or obtain other financing to support its product development testing and marketing operations and growth.

In addition to the foregoing, the Company’s actual future results could differ materially from those projected in the forward-looking statements as a result of the risk factors set forth in the Company’s various filings with the Securities and Exchange Commission and of the changes in general economic conditions, changes in interest rates and changes in the assumptions used in making such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

Agree | Disagree

Return to Contents